Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension

Pediatric Nephrology

Volumn 30, Issue 4, 2015, Pages 603-608

  Ohta, Toshiyuki ^a   Urayama, Kohtaro ^a   Tada, Yoshihiro ^a   Furue, Takeki ^a   Imai, Sayaka ^a   Matsubara, Keita ^a   Ono, Hiroaki ^a   Sakano, Takashi ^a   Jinno, Kazuhiko ^a   Yoshida, Yoko ^b   Miyata, Toshiyuki ^c   Fujimura, Yoshihiro ^b  

^a HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Anti C5 therapy; Atypical hemolytic uremic syndrome; Meningococcal infection; Pathological findings; Plasmapheresis resistant; Prophylactic antibiotics; Vaccination

Indexed keywords

CEFDINIR; COMPLEMENT COMPONENT C3; ECULIZUMAB; ENALAPRIL; FRESH FROZEN PLASMA; LOSARTAN; MENINGOCOCCUS VACCINE; NICARDIPINE; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CHOLELITHIASIS; CONTINUOUS HEMODIAFILTRATION; DISEASE ACTIVITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPERVOLEMIA; IMMUNOFLUORESCENCE; INFANT; KIDNEY BIOPSY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; PERITONEAL DIALYSIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; ATYPICAL HEMOLYTIC UREMIC SYNDROME; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT INACTIVATING AGENTS; HUMANS; HYPERTENSION, RENOVASCULAR; INFANT; MALE; PERITONEAL DIALYSIS; PLASMAPHERESIS;

EID: 84925483698     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2975-4     Document Type: Article

References (18)

1. Waters AM, Lichts C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26:41–57
2. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative-hemolytic uremic syndrome. Pediatr Nephrol 24:687–696
3. Tayler CM, Machin S, Wigmore SJ, Goodship THJ (2009) Clinical practice guideline for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148:37–47
4. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687
5. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657
6. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26:621–624
7. Kim JJ, Waller SC, Reid CJ (2012) Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 5:34–36
8. Vilalta R, Lara E, Madrid A, Chocron S, Munoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326
9. Nurnberger J, Witzke O, Opaza Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Eng J Med 360:542–544
10. Ishikura K, Uemura O, Ito S, Wada N, Hattori M, Ohashi Y, Hamasaki Y, Tanaka R, Nakanishi K, Kaneko T, Honda M; Pediatric CKD Study Group; Japan Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology (2013) Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan. Nephrol Dial Transplant 28:2345–2355
11. Ariceta G, Arrizabalaga B, Auirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710
12. Dorresteijn EM, van de Kar NCAJ, Cransberg K (2012) Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 27:1193–1195
13. Garjan M (2012) Early treatment with eculizumab may be beneficial in atypical heamolytic ureamic syndrome. Clin Kidney J 5:31–33
14. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T (2013) Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Eng J Med 368:2169–2181
15. Fakhouri F, Hourmant M, Campistol JM, Catalana SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weelers LE, Ogawa M, Bedrosian CL, Legendre CM (2013) Eculizumab inhibits thrombotic microangiopathy and improves renal function in adult atypical hemolytic uremic syndrome patients. J Am Soc Nephrol 24:49A–50A
16. Laszik Z (1996) Thrombotic microangiopathies. In: Silva F, D’Agati V, Nadasdy T (eds) Renal biopsy interpretation. Churchill Livingstone, New York, pp 283–308
17. Bouts A, Monnens L, Davin JC, Struijk G, Spanjaad L (2011) Insufficient protection by Neisseria meningitides vaccination alone during eculizumab therapy. Pediatr Nephrol 26:1918–1920
18. Ram S, Lewis LA, Rice PA (2010) Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23:740–780